⚡ Flash Summary

Ferozsons Laboratories Limited (FEROZ) reported its condensed interim financial information for the three months ended September 30, 2025. On a consolidated basis, net sales increased by 31% to Rs. 5.94 billion. The company’s gross profit margin improved to 41% from 39% in the same period last year, attributed to a shift in sales mix away from lower-margin institutional sales. Earnings per share (EPS) increased to Rs. 4.20, compared to Rs. 3.23 in the same period last year.

📌 Key Takeaways

• 🚀 Consolidated net sales increased by 31% to Rs. 5.94 billion.
• 📈 Standalone net sales grew by 16% to Rs. 3.88 billion.
• 💊 In-market generic sales increased by 21%.
• 📉 Institutional sales of generics and medical devices decreased by 1%.
• 💰 Gross Profit (GP) margin improved to 41% from 39%.
• 📊 Selling and distribution expenses increased by 30%.
• 💸 Administrative expenses increased by 16% due to inflationary impact.
• 📉 Finance costs decreased by 50% due to reduced policy rate by State Bank of Pakistan.
• 👍 Profit before tax grew by 50%.
• 📈 Profit after tax increased by 30%.
• 🧾 Effective tax rate closed at 39%, compared to 27% last year, due to change in tax regime for export sales.
• ⭐ Standalone earnings per share (EPS) closed at Rs. 4.20, compared to Rs. 3.23 last year.
• 🧪 BF Biosciences Limited sales increased by 75% to Rs. 2.43 billion.
• 💸 BF Biosciences Limited profit after tax increased by 38% to Rs. 160 million.

🎯 Investment Thesis

BUY: Ferozsons Laboratories demonstrates strong revenue growth and improved profitability. The company’s strategic shift towards higher-margin sales and efficient cost management makes it an attractive investment. Price Target: Rs. 7.50. Time Horizon: Medium Term.